[go: up one dir, main page]

SG11202008744VA - Injectable composition - Google Patents

Injectable composition

Info

Publication number
SG11202008744VA
SG11202008744VA SG11202008744VA SG11202008744VA SG11202008744VA SG 11202008744V A SG11202008744V A SG 11202008744VA SG 11202008744V A SG11202008744V A SG 11202008744VA SG 11202008744V A SG11202008744V A SG 11202008744VA SG 11202008744V A SG11202008744V A SG 11202008744VA
Authority
SG
Singapore
Prior art keywords
injectable composition
injectable
composition
Prior art date
Application number
SG11202008744VA
Inventor
Rodríguez Guillermo Franco
Aduriz Ibon Gutierro
Original Assignee
Laboratorios Farmaceuticos Rovi S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Farmaceuticos Rovi S A filed Critical Laboratorios Farmaceuticos Rovi S A
Publication of SG11202008744VA publication Critical patent/SG11202008744VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0017Filtration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0029Radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202008744VA 2018-06-12 2019-06-12 Injectable composition SG11202008744VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382413 2018-06-12
PCT/EP2019/065318 WO2019238740A1 (en) 2018-06-12 2019-06-12 Injectable composition

Publications (1)

Publication Number Publication Date
SG11202008744VA true SG11202008744VA (en) 2020-10-29

Family

ID=62716017

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008744VA SG11202008744VA (en) 2018-06-12 2019-06-12 Injectable composition

Country Status (33)

Country Link
US (2) US12226485B2 (en)
EP (1) EP3746047B1 (en)
JP (1) JP7420735B2 (en)
KR (1) KR20210019402A (en)
CN (1) CN112004525B (en)
AU (1) AU2019286572B2 (en)
BR (1) BR112020020415A2 (en)
CA (1) CA3096918A1 (en)
CL (1) CL2020002844A1 (en)
CO (1) CO2020012526A2 (en)
CY (1) CY1124772T1 (en)
DK (1) DK3746047T3 (en)
EA (1) EA202092021A1 (en)
ES (1) ES2900171T3 (en)
GE (1) GEP20237501B (en)
HR (1) HRP20211874T1 (en)
HU (1) HUE057269T2 (en)
IL (1) IL277802B2 (en)
LT (1) LT3746047T (en)
MA (1) MA52502B1 (en)
MD (1) MD3746047T2 (en)
MX (1) MX2020011732A (en)
PE (1) PE20210047A1 (en)
PH (1) PH12020551740A1 (en)
PL (1) PL3746047T3 (en)
PT (1) PT3746047T (en)
RS (1) RS62681B1 (en)
SG (1) SG11202008744VA (en)
SI (1) SI3746047T1 (en)
SM (1) SMT202100678T1 (en)
UA (1) UA127087C2 (en)
WO (1) WO2019238740A1 (en)
ZA (1) ZA202006113B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022046578A1 (en) * 2020-08-25 2022-03-03 Merck Sharp & Dohme Corp. Injectable depot compositions for the delivery of antiviral agents

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
BE758156R (en) 1970-05-13 1971-04-28 Ethicon Inc ABSORBABLE SUTURE ELEMENT AND ITS
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4523591A (en) 1982-10-22 1985-06-18 Kaplan Donald S Polymers for injection molding of absorbable surgical devices
JP2670680B2 (en) * 1988-02-24 1997-10-29 株式会社ビーエムジー Polylactic acid microspheres containing physiologically active substance and method for producing the same
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5620700A (en) 1990-10-30 1997-04-15 Alza Corporation Injectable drug delivery system and method
ES2236700T3 (en) 1993-11-19 2005-07-16 Janssen Pharmaceutica N.V. 1,2-MICROENCAPSULATED BENZAZOLS.
EP0959873B1 (en) 1996-12-20 2006-03-01 ALZA Corporation Gel composition and methods
KR100289471B1 (en) 1998-01-19 2001-09-17 김충섭 A controlled/sustained implant delivery containing fentanyls
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
DE10190041D2 (en) 2000-01-11 2002-12-05 Roland Bodmeier Implants, particles
US6604561B2 (en) 2000-02-11 2003-08-12 Medical Instill Technologies, Inc. Medicament vial having a heat-sealable cap, and apparatus and method for filling the vial
CN1211076C (en) 2000-02-17 2005-07-20 3M创新有限公司 Delivery devices and methods using preformed biodegradable polymer compositions
WO2002038185A2 (en) 2000-11-13 2002-05-16 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
WO2004064752A2 (en) 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
WO2004081196A2 (en) 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
CA2915574C (en) 2003-07-18 2017-02-07 Oakwood Laboratories, L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
GB0420016D0 (en) 2004-09-09 2004-10-13 Leuven K U Res & Dev Controlled release oral delivery system
AU2005294382A1 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
DE102005031868A1 (en) 2005-07-04 2007-01-18 Biotronik Vi Patent Ag Drug depot for parenteral, especially intravascular drug release
GB0517673D0 (en) 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
UA95088C2 (en) * 2005-10-21 2011-07-11 Панасеа Биотек Лтд. Composition comprising at least one anticancer drug and at least one polymer and reducing chemotherapy-induced alopecia, process for the preparation thereof
EA200970348A1 (en) 2006-10-05 2009-10-30 Панацея Биотек Лтд. NEW INJECTABLE DEPOSIT COMPOSITIONS AND METHOD OF OBTAINING SUCH COMPOSITIONS
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
FR2908775B1 (en) 2006-11-17 2012-08-31 Biomatlante HYDROGEL AND ITS BIOMEDICAL APPLICATIONS
PL2115029T3 (en) 2007-02-15 2016-01-29 Tolmar Therapeutics Inc Low burst poly-(lactide/glycolide) and methods to produce polymers
ES2606951T3 (en) 2007-05-18 2017-03-28 Durect Corporation Enhanced extended release formulations
US10010612B2 (en) 2007-05-25 2018-07-03 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
CL2008003305A1 (en) * 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Injectable composition comprising an active agent selected from a defined group; at least one bioerodible polymer, at least one non-toxic solvent and optionally one or more excipients; Preparation process; use to treat mental illness or cancer.
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US20100144687A1 (en) 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
ES2390439B1 (en) 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. INJECTABLE COMPOSITION
US10285936B2 (en) * 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
SI2394664T1 (en) 2010-05-31 2016-10-28 Laboratorios Farmaceuticos Rovi, S.A. Antipsychotic injectable depot composition
PL2394663T3 (en) 2010-05-31 2022-02-21 Laboratorios Farmaceuticos Rovi, S.A. Compositions for injectable in-situ biodegradable implants
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
MX347014B (en) 2010-11-24 2017-04-07 Durect Corp Biodegradable drug delivery composition.
DK2529756T3 (en) 2011-05-31 2021-08-02 Farm Rovi Lab Sa Risperidone and / or paliperidone implant formulation
DK2529757T3 (en) 2011-05-31 2014-02-24 Rovi Lab Farmaceut Sa Paliperidonimplantatformulering
CN102512399B (en) * 2011-12-31 2013-05-01 湖南赛沃药业股份有限公司 Long-acting naltrexone implant and preparation method thereof

Also Published As

Publication number Publication date
MX2020011732A (en) 2021-01-08
EP3746047A1 (en) 2020-12-09
CA3096918A1 (en) 2019-12-19
WO2019238740A1 (en) 2019-12-19
JP2021527627A (en) 2021-10-14
HRP20211874T1 (en) 2022-03-04
HUE057269T2 (en) 2022-05-28
AU2019286572A1 (en) 2020-10-01
UA127087C2 (en) 2023-04-05
IL277802B1 (en) 2023-12-01
KR20210019402A (en) 2021-02-22
PE20210047A1 (en) 2021-01-08
US20210154302A1 (en) 2021-05-27
SI3746047T1 (en) 2022-02-28
AU2019286572B2 (en) 2025-01-02
SMT202100678T1 (en) 2022-03-21
IL277802A (en) 2020-11-30
JP7420735B2 (en) 2024-01-23
PH12020551740A1 (en) 2021-06-07
CN112004525A (en) 2020-11-27
US20250144218A1 (en) 2025-05-08
CO2020012526A2 (en) 2020-12-10
MD3746047T2 (en) 2022-02-28
GEP20237501B (en) 2023-04-25
BR112020020415A2 (en) 2021-03-02
MA52502B1 (en) 2021-12-31
EP3746047B1 (en) 2021-10-13
IL277802B2 (en) 2024-04-01
DK3746047T3 (en) 2021-12-06
PL3746047T3 (en) 2022-02-07
CN112004525B (en) 2024-09-13
CL2020002844A1 (en) 2021-03-05
MA52502A (en) 2020-12-09
CY1124772T1 (en) 2022-11-25
RS62681B1 (en) 2021-12-31
ES2900171T3 (en) 2022-03-16
US12226485B2 (en) 2025-02-18
LT3746047T (en) 2022-01-10
ZA202006113B (en) 2022-12-21
EA202092021A1 (en) 2021-03-23
PT3746047T (en) 2021-11-26

Similar Documents

Publication Publication Date Title
GB201911800D0 (en) Antiflouling Composition
GB201810492D0 (en) Composition
GB2583851B (en) Composition
GB201811100D0 (en) Composition
GB2606975B (en) Composition
GB201820878D0 (en) Composition
GB201909924D0 (en) Composition
GB201804434D0 (en) Composition
GB201818827D0 (en) Composition
PL3571933T3 (en) Composition
GB201801596D0 (en) Composition
EP3858377A4 (en) Injectable composition
GB201901161D0 (en) Composition
IL277802A (en) Injectable composition
GB201819861D0 (en) Composition
GB201815032D0 (en) Composition
GB201810024D0 (en) Composition
GB201809123D0 (en) Composition
GB201913398D0 (en) Composition
HK40038956B (en) Injectable composition
GB201820082D0 (en) Composition
GB201818567D0 (en) Composition
GB201815704D0 (en) Composition
GB201815420D0 (en) Composition
GB201813442D0 (en) Composition